Search

Displaying results 2071 - 2080 of 10000 in total
  1. Drug

    RDP58

    go.drugbank.com/drugs/DB06566
    Experimental

    RDP58 (NH2-arg-norleucine (nle)-nle-arg-nle-nle-nle-gly-tyr-CONH2) (Sangstat Corp., Fremont, California) is a novel synthetic peptide that inhibits early signal transduction pathways for the expression

    Categories: Histocompatibility Antigens Class I
  2. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid

  3. Drug

    P-57AS3

    go.drugbank.com/drugs/DB06569
    Experimental

    Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A Inhibitors
  4. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Categories: Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic IndexProducts: VOTRIENT® 200 MG, VOTRIENT® 400 MG
  5. Drug

    TD101

    go.drugbank.com/drugs/DB06596
    Investigational

    TD101, a small interfering RNA (siRNA) designed for the treatment of pachyonychia congenita

  6. Drug

    Nemonoxacin

    go.drugbank.com/drugs/DB06600
    Investigational

    Categories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP1A2 Inhibitors
  7. Drug

    Panobinostat

    go.drugbank.com/drugs/DB06603
    ApprovedInvestigational

    Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … Panobinostat is marketed by Novartis under the brand name Farydak.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-
  8. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab (teplizumab-mzwv) is a humanized IgG1 kappa CD3-directed monoclonal antibody used to delay the onset of type 1 diabetes (T1D). … [A241480,A241045,A241475,L44091] T1D is an autoimmune condition in which T cell-mediated destruction of pancreatic β cells leads to loss of insulin production, impaired glycemic control, and reliance on

  9. Drug

    Catumaxomab

    go.drugbank.com/drugs/DB06607
    ApprovedWithdrawn

    Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. … It is currently available under the brand name Removab.

  10. Drug

    Peramivir

    go.drugbank.com/drugs/DB06614
    ApprovedInvestigational

    Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. … The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.

    Products: Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (3 Adet), Influviran 200 mg/20 mL IV İnfüzyonluk Çözelti Hazırlamak İçin Konsantre (5 Adet)